Trefoil peptides (TFFs) are now considered as scatter factors, proinvasive and angiogenic agents acting through cyclooxygenase-2 (COX-2)-and thromboxane A2 receptor (TXA2-R)-dependent signaling pathways. As expression and activation levels of the epidermal growth factor receptor (EGFR) predict the metastatic potential of human colorectal cancers, the purpose of this study was to establish whether the EGF receptor tyrosine kinase (EGFR-TK) contributes to cellular invasion induced by TFFs in kidney and colonic cancer cells. Both the dominant negative form of the EGFR (HER-CD533) and the EGFR-TK inhibitor ZD1839 (Iressa) abrogated cellular invasion induced by pS2, spasmolytic polypeptide (SP) and the src oncogene, but not by ITF and the TXA2-R. Similarly, EGFR-TK inhibition by ZD1839 reversed the invasive phenotype promoted by the constitutively activated form of the EGFR (EGFRvIII) and the EGFR agonists transforming growth factor alpha (TGFa), amphiregulin and EGF. We also provide evidence that TFFs, EGFRvIII, and TGFa trigger common proinvasive pathways using the PI3 0 -kinase and Rho/Rho-kinase cascades. These findings identify the EGFR-TK as a key signaling element for pS2-and SP-mediated cellular invasion. It is concluded that although pS2, SP and ITF belong to the same family of inflammation-and cancerassociated regulatory peptides, they do not control identical signaling networks.
Introduction
Trefoil peptides (TFFs) constitute a family of structurally related peptides (Hoffmann and Jagla, 2002) comprising pS2 (TFF1), spasmolytic polypeptide (SP) (TFF2) and intestinal trefoil factor ITF (TFF3). TFFs are mainly expressed in the gastrointestinal tract and share a highly conserved motif comprised of six conserved cysteine residues responsible for the trefoil structure. In the gastrointestinal mucosa, TFFs are associated and cosecreted with mucins in mucin-secreting epithelial cells (Newton et al., 2000; Tomasetto et al., 2000) . Moreover, TFFs are implicated in the repair of the gastric mucosa by enhancing epithelial cell migration (Dignass et al., 1994; Williams et al., 1996) . Both SP and ITF protect epithelial cells from apoptosis (Lalani et al., 1999; Chen et al., 2000; Taupin et al., 2000) . Thus, TFFs play an important role against injurious agents, including gastric acid, digestive enzymes and pathogens (Kindon et al., 1995; Mashimo et al., 1996; Playford et al., 1996) . TFFs are aberrantly expressed during chronic inflammatory disorders such as Crohn's disease, colitis or gastric ulceration Wright et al., 1993; Tran et al., 1999) , and are overexpressed in a wide range of human solid tumors of breast, urogenital and gastrointestinal tract (Theisinger et al., 1991; Taupin et al., 1996; May and Westley, 1997) . Taken together, these observations postulate that in normal digestive mucosa, TFFs exert a beneficial role on wound healing and restitution of the injured digestive epithelia.
Several clinical studies suggest a strong correlation between chronic inflammatory diseases and cancer progression (Rosam et al., 1986; Giovannucci et al., 1995) . It is of interest to note that TFFs are functioning as scatter factors, proinvasive and angiogenic agents, suggesting that TFFs might play a critical role in the establishment and progression of colonic tumors during the adenoma/adenocarcinoma transition Rodrigues et al., 2001 Rodrigues et al., , 2003 . Consequently, TFFs might exert undesirable effects on the emergence and progression of digestive tumors linked to chronic inflammatory diseases and during early steps of tumorigenesis controlled by constitutive oncogenic defects, such as RAS and SRC activation.
However, little is still known about the signaling pathways linked to the biological actions of the TFFs. We have shown that cellular invasion induced by external addition of TFFs or constitutive overexpression of pS2 is dependent on cyclooxygenase COX-2 and thromboxane A2 receptor (TXA2-R) activities (Rodrigues et al., 2001) . Recent studies suggest that the mitogenic effect of SP and ITF is synergistically enhanced by EGF in vitro (Chinery and Playford, 1995; Oertel et al., 2001) . This leads to the question whether EGFR is required for the proinvasive activity of TFFs. EGFR is a tyrosine kinase receptor that belongs to the ErbB receptor family comprising four members. EGFR is activated by the extracellular binding of several ligands such as EGF, TGFa, amphiregulin, betacellulin, epiregulin, heparin binding EGF, epigen, and the neuregulins that induce its dimerization in homo or heterodimers, leading to EGFR autophosphorylation. This tyrosine phosphorylation leads to the downstream activation of several signaling pathways including mitogen-activated protein kinase (MAPK) and PI3 0 -K (Yarden, 2001) . Thus, EGFR plays a pivotal role in a complex signal transduction network that leads to cellular transformation through the modulation of cell scattering, migration, proliferation, apoptosis, adhesion and differentiation.
Genetic alterations, overexpression and constitutive activation of EGFR were frequently reported in human solid tumors of breast, colon, kidney and prostate (Gullick, 1991; Radinsky et al., 1995; Salomon et al., 1995) . The most frequent alteration of the EGFR gene is an in-frame deletion encompassing exons 2-7, encoding a truncated receptor lacking 267 amino acids in the extracellular domain, known as EGFRvIII (Yamazaki et al., 1988; Wong et al., 1992) . EGFRvIII fails to bind ligands but still has the ability to dimerize, so its tyrosine kinase is constitutively activated. Thus, this truncated EGFR undergoes autophosphorylation and initiates signaling cascades (Moscatello et al., 1996; Prigent et al., 1996; Huang et al., 1997) . The ectopic expression of EGFRvIII in NIH3T3 cells causes a transformed phenotype, which underlines the essential role of EGFR activation in tumorigenesis (Moscatello et al., 1996) . Frequent expression of this mutant in various human cancers suggests that it could confer a strong advantage to tumor cells in vivo. Moreover, EGFR has been shown to stimulate migration and invasion of both normal and tumor cells (Price et al., 1996; Turner et al., 1996; Xie et al., 1998) . This implies that aberrant activation of EGFR may promote cellular transformation, cancer growth, and the metastatic phenotype.
In this study, we investigated the possible implication of EGFR in the proinvasive properties of the TFFs pS2, SP and ITF in kidney and colonic cancer cells. For this purpose, we compared the efficiency of the EGFR tyrosine kinase inhibitor ZD1839 (Ciardiello et al., 2000; Ciardiello and Tortora, 2001 ) and the HER-CD533 dominant-negative form of EGFR lacking its intracellular domain (Redemann et al., 1992) to inhibit collagen gel invasion induced by TFFs. We show that both ZD1839 and HER-CD533 abolished the invasiveness induced by pS2 and SP, but not ITF. Furthermore, in order to elucidate the pathways implicated in EGFR activation and the invasive phenotype during colorectal tumorigenesis, we have examined the proinvasive actions of its natural agonists (TGFa, EGF and amphiregulin) and its constitutively activated form EGFRvIII that mimics the overexpression and activation of EGFR in gastric cancers Moscatello et al., 1996; Huang et al., 1997) . Both natural EGFR ligands and EGFRvIII promoted cellular invasion, and this effect was abrogated by EGFR tyrosine kinase inactivation. Here, we also provide evidence that invasion induced by TGFa, EGFRvIII and TFFs triggered both common and divergent proinvasive signaling pathways.
Results

Selective inhibition of cellular invasion by the EGFR tyrosine kinase inhibitor ZD1839
As shown in Figure 1 , ZD1839 selectively and dosedependently abrogated cellular invasion induced by the src oncogene and the TFFs pS2 and SP in the kidney epithelial cell line MDCKts.src, with a potency IC 50 of 80-300 nm. In tyrosine kinase assays, the inhibitory potency of ZD1839 on the EGFR tyrosine kinase occurs at IC 50 ranging from 30 to 80 nm (Wakeling et al., 2002) . In fact, both src and EGFR can interact bidirectionally because src activation by upstream signals can result in ligand-independent activation and phosphorylation of the EGFR at tyrosines Y-845, -891 and -920 that are not the autophosphorylation sites (Carpenter, 1999) . Conversely, activation of src following EGFR activation by external ligands is observed. Moreover, such interplay can lead to synergistic biological responses, including the enhancement of the mitogenic response to EGF observed in src-transformed cells (Tice et al., 1999) . This reciprocal crosstalk might interfere with the potency of ZD1839 at the src/EGFR self-activation cascade since this inhibitor has much lower activity against src and the EGFR-related tyrosine kinases HER2 and KDR (IC50 Figure 1 Selective inhibition of cellular invasion by the EGFR tyrosine kinase inhibitor ZD1839 in kidney epithelial cells MDCKts.src exposed to TFFs or transformed by the src oncogene. Invasion index in collagen type I gels was measured in MDCKts.src cells transformed by the SRC oncogene ('), or incubated for 24 h at the nonpermissive temperature 401C, in the presence or absence of the following TFFs (100 nm): pS2 (m), SP (~) or ITF (), either alone or combined with various concentrations of ZD1839. Data are means7s.e.m. from three experiments EGFR signaling in TFF-induced cellular invasion S Rodrigues et al of 3.7-20 mm). In contrast, the EGFR tyrosine kinase inhibitor was totally ineffective against invasiveness promoted by the intestinal trefoil factor ITF in MDCKts.src cells. Similarly, ZD1839 was ineffective against invasion induced by ITF and the TXA2-R agonist U466 in the human colonic cell line HCT8/S11 (Figure 2) , and ZD1839 completely blocked this cellular activity induced after external addition of the trefoil factor pS2 or its constitutive expression in HCT8/S11-pS2 cells stably transformed by the pS2 cDNA. As previously reported Rodrigues et al., 2001) , this latter situation mimics the overexpression of the trefoil factor pS2 observed during chronic inflammatory diseases and the neoplasic progression in the human digestive tract.
In order to confirm the implication of the EGFR in the proinvasive actions of the TFFs pS2 and SP, we have established stable cell lines expressing a dominantnegative form of the EGFR (HER-CD533), lacking its intracellular domain. This mutant undergoes EGFinduced receptor dimerization and forms inactive heterodimers with resident wild-type receptors. We have therefore produced several HER-CD533-expressing clonal derivatives after transfection of MDCKts.src and HCT8/S11 cells with the pcDNA3-HER-CD533 vector ( Figure 3 ). First, we have verified the functionality of this expression vector after transient transfection of the human kidney epithelial cell line HEK-293 T (not shown). Both MDCKts.src-HER-CD533 (clone 8, pools 1 and 2) and HCT8/S11-HER-CD533 variants (clones 1, 7 and pools 1 and 2) were validated for HER-CD533 expression by Western blot, using a specific antibody against the Flag epitope encoded by the recombinant HER-CD533 construct, as shown in Figure 3a and b. This 115 kDa HER-CD533 band is absent in control HEK-293 T kidney cancer cells, and mock-transfected MDCKts.src and HCT8/S11 cells, using the corresponding empty vector pcDNA3 (Figure 3a and b). In agreement with our ZD1839 data, the EGFR domi- Figure 2 Selective inhibition of cellular invasion by the EGFR tyrosine kinase inhibitor ZD1839 in the human colonic cancer cell line HCT8/S11 exposed to TFFs and the TXA2-R agonist U466 or transformed by pS2. Invasion index in collagen type I gels was measured using pS2-transformed HCT8/S11 cells (HCT8/S11-pS2), or HCT8/S11 cells exposed for 24 h to the external addition of 100 nm of the TFFs pS2 and ITF, or 10 mm of the TXA2-R agonist U466, either alone (clear bars) or combined with 1 mm ZD1839 (filled bars). Data are means7s.e.m. from three experiments Figure 3 Selective inhibition of cellular invasion by the dominant-negative form of EGFR (HER-CD533) in MDCKts.src and HCT8/ S11 cells exposed to the trefoil factors pS2 and ITF, or the TXA2-R agonist U466. Expression of the dominant-negative form of EGFR (HER-CD533) in stably transfected MDCKts.src cells (a) and HCT8/S11 (b) cells was analysed by Western blot, using the monoclonal antibody M2 against the Flag epitope present in the recombinant HER-CD533 protein (MW: 115 kDa). Invasion index was measured using the MDCKts.src and HCT8/S11 parental cells (control: clear bars) or their HERCD533-transfected counterparts (filled bars) incubated for 24 h in the presence of the trefoil factors (100 nm) pS2 and ITF, or the TXA2-R agonist U466 (10 mm). Data are means7s.e.m. from three experiments EGFR signaling in TFF-induced cellular invasion S Rodrigues et al nant-negative mutant HER-CD533 completely reversed cellular invasion induced by pS2 in the two models, but had no effect on invasion promoted by ITF and the TXA2-R agonist U466. As expected, HER-CD533 also blocked cellular invasion in HCT8/S11 colonic cancer cells exposed to cholic acid, lithocholic acid and chenodeoxycholic acid (Figure 4) . Indeed, bile acids induced EGFR phosphorylation and enhanced COX-2 expression in the KMBC human cholangiocarcinoma cell line (Yoon et al., 2002) . In this connection, we have recently demonstrated that bile acids promote the invasive phenotype in human colonic cancer cells through COX-2-and Rho-GTPasesdependent signaling pathways (Debruyne et al., 2002) .
Invasion patterns induced by the EGFR natural agonists
EGFR is directly activated by a vast family of regulatory growth factors including EGF, TGFa and amphiregulin (Yarden, 2001) . Both EGF and TGFa are overexpressed in the transformed gastrointestinal tract and are therefore acting as paracrine/autocrine agents during cancer progression (Ziober et al., 1993; Jiang et al., 1998; Messa et al., 1998; Wang et al., 1998; Normanno et al., 2001) . In order to specify the role of EGFR activation in cellular invasion, we studied the invasion patterns of kidney and colonic cancer cells in response to its natural agonists including EGF, TGFa and amphiregulin. We first established the doseresponse curves of these three EGFR ligands on cellular invasion, using MDCKts.src cells (Figure 5a ). These EGFR agonists promoted the invasive phenotype in MDCKts.src cells, according to parallel dose-response curves. TGFa was more potent (EC 50 ¼ 0.1 nm) than amphiregulin (EC 50 ¼ 0.4 nm) or EGF. Using the stably transfected MDCKts.src-HER-CD533 cell line, we next demonstrated that the dominant-negative form of EGFR abolished the invasiveness induced by these natural ligands (Figure 5b) . Therefore, the implication of the EGFR in the proinvasive activities of pS2 and SP is connected with its capacity to promote the same cellular responses after the activation of its extracellular binding domain by its natural ligands. Most importantly, these EGFR agonists were also effective in inducing collagen type 1 invasion by the premalignant PC/AA/C1 cell line established from a polyp isolated from a patient with an FAP familial adenomatosis polyposis ( Figure 6 ). Similar results were obtained using the PCmsrc cell line subsequently transformed by c-SRC oncogene. Thus, we elucidate here a new proinvasive signaling pathway potentially involved in the adenomaadenocarcinoma transition after activation of the EGFR by its physiologically relevant agonists.
Signaling pathways triggered by constitutive EGFR activation
Apart from direct activation of the EGFR by its natural ligands via autocrine/paracrine loops and its transactivation by G-protein-coupled serpentine receptors (Prenzel et al., 1999; Pai et al., 2002) , the EGFR pathways are frequently upregulated through genomic amplification and overexpression of the EGFR binding site, and its constitutive activation in a wide range of human cancers. The most common mutations in the EGFR gene corresponds to deletions of exons 2-7 (Yamazaki , 1988; Wong et al., 1992) in the EGFRvIII variant lacking part of the N-terminal tail (amino acids 6-273) within the extracellular binding domain. Such a truncated EGFRvIII form is constitutively phosphorylated and activated in a ligand-independent dimerization process.
In order to confirm that the EGFR tyrosine kinase plays a critical role in cellular invasion, we established two HCT8/S11 clonal derivatives stably transfected with the EGFRvIII cDNA. The functionality of the vector has been verified in transiently transfected HEK-293 T cells, and the corresponding HCT8/S11-EGFRvIII variants were validated by Western blot (clones 2 and 5), using a specific antibody directed against the intracellular domain of EGFR, as shown in Figure 7a . The expected EGFRvIII-positive band migrates as a 140 kDa protein since the full-length wild-type EGFR is 175 kDa glycoprotein. This 140 kDa labeling of EGFRvIII is not detected in kidney cancer cells HEK-293 T and control HCT8/S11 cells (Cont) transfected by the corresponding empty vector (Figure 7a ). As shown in Figure 7a (inset), we first noticed that constitutive activation of the EGFR in the HCT8/S11-EGFRvIII variants induced a spontaneous invasive phenotype. Interestingly, constitutive invasiveness promoted by the EGFRvIII mutant was fully abrogated by the selective EGFR tyrosine kinase inhibitor ZD1839 in a dosedependent manner, with a potency IC 50 ¼ 20 nm. This inhibitory potency is in agreement with the IC 50 value of 30-80 nm obtained for this synthetic anilinoquinazoline on the EGFR tyrosine kinase in vitro (Moasser et al., 2001; Wakeling et al., 2002) . Thus, one can postulate that ZD1839 may improve the treatment of patients bearing solid tumors harboring EGFR amplification, constitutive transactivation, and expressing the EGFRvIII mutant.
We next characterized and compared the signaling pathways involved in the proinvasive activity of EGFRvIII on one hand (Figure 7a ) and the EGFR ligand TGFa on the other (Figure7b) . The invasive phenotype induced by EGFRvIII and TGFa was abrogated by ZD1839, the PI3 0 -kinase inhibitor wortmannin (WORT), and the pharmacological inhibitors of the Rho-ROCK pathway (C3 T and Y27632). Similarly, pertussis toxin (PTx) fully reversed the stimulatory action of TGFa on parental HCT8/S11 cells (invasion index, 11.271.4%) and the constitutive invasiveness measured in EGFRvIII-transformed HCT8/S11 cells (10.371.7%). Residual invasion index measured in the presence of 100 ng/ml PTx were, respectively, 1.470.6 and 2.170.3%. PTx affects both Gao/i signaling and the redistribution of their Gbg-associated G-protein Figure 7 Signaling pathways implicated in cellular invasion induced by the constitutively activated form of EGFR (EGFRvIII) and the EGFR agonist TGFa in the human colonic cancer cell line HCT8/S11. (a) The expression of EGFRvIII (140 kDa) in stably transfected colonic HCT8/S11-EGFRvIII cells was analysed by Western blot (clones 2 and 5), using a monoclonal antibody against the C-terminal domain of EGFR. HCT8/S11-EGFRvIII cells were then incubated for 24 h in the presence of increasing concentrations of the EGFR tyrosine kinase inhibitor ZD1839 (inset). (b) Parental colonic HCT8/S11 cells were incubated for 24 h in the presence or absence (Cont) of TGFa (20 nm), either alone or combined with one of the following inhibitors of signal transduction pathways: EGFR (ZD1839, 1 mm), PI3 0 -K (wortmannin: WORT, 10 nm), Rho/ROCK cascade (respectively, C3 T, 5 mg/ml and Y27632, 10 mm), COX-2 (NS-398, 100 nm) and thromboxane A2 receptor (TXA2-R: SQ295, 10 mm). Data are means7s.e.m. from four experiments EGFR signaling in TFF-induced cellular invasion S Rodrigues et al heterodimers. These G-protein subunits are critically linked to several oncogenic pathways, including EGFR transactivation, and signaling through src and Rho GTPases. For example, Gbg subunits activate ras/ MAPKs by a pathway common to activated EGFR binding the Shc-Grb2-Sos complex (Van Biesen et al., 1995) , while PTx-sensitive Gai subunits can promote convergent activation of the MAPK pathway (Daub et al., 1997) , and activation of arachidonic acid metabolism into prostaglandins, primarily of the PGE2 family that have been implicated in cellular invasion (Dohadwala et al., 2002) . Accordingly, ligandactivated EGFR was shown to stimulate the Ras/Raf/ MAP kinase pathway linked to the AP1 transcriptional cascade, through recruitment of the Shc-Grb2-SOS complex, leading to ras activation or recruitment of PLCg and subsequent PKC activation. Other EGFRmediated signals include activation of the stress-activated protein kinases JNK and p38, the PI3 0 -K pathway and the Janus kinase/signal transducers and activators of transcription. Since we have recently demonstrated that the proinvasive activity of TFFs was dependent on the COX-2/TXA2-R cascade (Rodrigues et al., 2001 ), we next examined the possible contribution of these pathways in EGFRvIII-and TGFa-stimulated invasion, using their corresponding specific inhibitors NS-398 and SQ295. Interestingly, we pointed out here that similarly to cellular invasion mediated by TFFs, invasiveness promoted by EGFRvIII required COX-2 and TXA2-R activities (Figure 7a ). In contrast, these two inhibitors were ineffective on cellular invasion induced by TGFa (Figure 7b ). Our data indicate that invasiveness induced by ligand-activated wild-type EGFR and the constitutively activated mutant EGFRvIII did not trigger similar downstream signaling pathways.
Discussion
The hallmark of colon cancer progression from early premalignant stages, including the formation of aberrant crypt foci and adenomas, is the subsequent acquisition of the invasive phenotype that allows tumor cells to invade distant organs during the metastatic cascade. Our laboratory focused on the characterization of transforming growth factors secreted by the tumor stroma and cancer cells, and their relative contribution to the progression of digestive cancers controlled by oncogenes. Recently, we have reported data supporting the notion that TFFs act as transforming growth factors in the colonic mucosa during inflammatory disorders and neoplastic progression, via autocrine and paracrine loops. TFFs are involved in tumor cell scattering, invasion, and function as survival factors and proangiogenic agents in vitro and in vivo Rodrigues et al., 2001; Bossenmeyer-Pourie´et al., 2002; Regnauld et al., 2002; Rodrigues et al., 2003) . Most of these transforming functions controlled by TFFs are also shared by the EGFR (Shibamoto et al., 1994) . At this point, one can postulate that the TFF signaling pathways may serve as potential targets in the control of colon cancer progression and other human solid tumors concerned by aberrant overexpression of TFFs.
Several studies aimed to identify the signaling pathways implicated in the biological functions of TFFs in the central nervous system and peripheral tissues (Hoffmann et al., 2002 ). In the current study, our main hypothesis assumed the potential implication of the EGFR in cellular invasion induced by TFFs. In this connection, we also compared the proinvasive signaling pathways induced by TFFs, EGFR agonists and the constitutively activated mutant EGFRvIII. Recently, the importance of the EGFR signaling pathways in the malignant behavior of human colon carcinomas and glioblastomas has been challenged (Radinsky et al., 1995; Lal et al., 2002) . The EGFR (ErbB1/HER1) is the prototype of the ErbB family of membrane receptors that include ErbB2 (HER2,neu), ErbB3 (HER3) and ErbB4 (HER4). ErbBs are also activated via a process of receptor homo-and heterodimerization involving almost every possible dimeric combinations between ErbBs (Brennan et al., 2000; Olayioye et al., 2000) . The EGFR can form molecular scaffolds with the platelet-derived growth factor b receptor and PI3 0 -K, in an src-dependent manner (Habib et al., 1998; Saito et al., 2001) , or with urokinase plasminogen activator receptor (uPAR) complexed with a5b1 integrins, in a fibronectinand focal adhesion kinase FAK-dependent manner (Liu et al., 2002) . High expression levels of EGFR, ErbB2 and pS2 have been frequently observed in breast, colon, prostate and ovarian tumors (Dante et al., 1994; Ozgul et al., 1997; Emami et al., 2001) . Overexpression of EGFR positively correlates with the metastatic potential, shortened survival and increased relapses rates in human solid tumors (Radinsky et al., 1995; Maurizi et al., 1996; Gilbertson et al., 1997; Tong et al., 1998) . The recent report that EGFRvIII induces a specific pattern of genes implicated in tumor invasion led to the proposal that EGFR is a critical effector implicated in the dissemination of solid tumors (Lal et al., 2002) . These target genes include matrix metalloproteinases (MMP-1/MMP-13) and cellular matrix components, such as collagen.
Using the EGFR tyrosine kinase inhibitor ZD1839 and the dominant-negative HER-CD533 mutant, we provided evidence that cellular invasion stimulation by external addition of pS2 and SP, or constitutive expression of pS2, is strictly dependent upon EGFR tyrosine kinase activity and signaling pathways (Figure 8 ). TFFs and EGFRvIII stimulate cellular invasion through the same oncogenic pathways, including PI3 0 -K, the Rho-ROCK cascade and the COX-2/ TXA2-R signaling. Accordingly, EGFR dimerization activates its intrinsic tyrosine kinase to create a series of docking sites for signaling elements that include Cb1, Grb2 (at tyrosine Y1068 and 1086), Shc (at Y1148 and 1173), PLCg and the class I PI3 0 -K adaptor p85, and indirectly, via the EGFR-Grb2-associated binder Gab-1 or p85-ErbB-3/EGFR heterodimers (Prigent and Gullick, 1994; Rodrigues et al., 2000; Yart et al., 2001) .
Recruitment of the class II PI3
0 -K enzyme is also observed at phosphotyrosine residues Y992, Y1068 and Y1173 on activated EGFR, through the Grb2 adaptor (Arcaro et al., 2000; Olayioye et al., 2000; Wheeler and Domin, 2001 ). The PI3 0 -K enzymes are now well recognized as critical mediators of invasiveness of immune and cancer cells (Kotelevets et al., 1998; Barbier et al., 2001) . Moreover, it has been shown that EGFR activation upregulated COX-2 expression and inversely, that COX-2 overexpression induced EGFR expression in colon cancer cells (Coffey et al., 1997; Kinoshita et al., 1999) . The importance of COX-2 signaling in establishment and maintenance of adenomas has been recently recognized with the development of nonsteroidal antiinflammatory drugs (NSAIDs) in patients with familial adenomatous polyposis (FAP) since NSAIDs reduce the number and size of adenomas in FAP patients (Labayle et al., 1991; Giardiello et al., 1993; Jacoby et al., 1996) . Cyclooxygenases generate several prostanoids, including prostaglandins PGE2, PGF2a, PGD2, PGI2 and TXA2. Both prostaglandins and TXA2 function as proinvasive agents and are controlled by pS2 signaling through an src-dependent autoactivation loop (Rodrigues et al., 2001) . The G-protein-coupled prostaglandin receptors were recently shown to transactivate the EGFR through metalloprotease-mediated release of the EGFR ligand and c-src association with the EGFR (Pai et al., 2002) . Similarly, transactivation of the EGFR has been reported after short-term activation by the G-proteincoupled receptor agonists thrombin, lysophosphatidic acid and endothelin (Daub et al., 1996) . Most interestingly, transactivation of the EGFR has been described through a molecular complex comprising the G-proteincoupled b2 adrenergic receptor and EGFR (Maudsley et al., 2000) . In the present study, PTx abolished cellular invasion promoted by EGFRvIII and external addition of the EGFR ligand TGFa, as previously shown for EGFR (Yang et al., 1993) . The PTx-sensitive G-proteins Gai control exocytosis and release of preformed mediators, such as prostaglandins and leukotrienes. On the other hand, Gbg dimers liberated from activated trimeric G-proteins are also connected with several proinvasive signaling pathways controlled by TFFs, ras, src and the Met oncogenes . In turn, EGFR and TFFs share common biological and transforming cellular functions regarding regeneration of the intestinal epithelium, migration and wound healing, protection against apoptosis, scattering and proinvasive activities, as shown in the present study. However, invasiveness mediated by ITF was insensitive to both ZD1839 and HER-CD533, indicating that the ITF proinvasive signaling pathways are EGFR-independent. Accordingly, stimulation of intestinal epithelial cell migration by ITF correlated with activation of ERK1/2 mitogen-activated protein kinase, independently of EGFR phosphorylation . This result emphasizes that while pS2, SP and ITF are closely related peptides at the structural and functional levels, they do not trigger the same downstream proinvasive signaling pathways. This observation brings back the interesting question regarding the identity of the putative TFFs receptors involved in the initiation of signaling cascades. Until now, the main idea was that TFFs interact with the same recognition sites. It has been reported that pS2 and ITF can associate together in human intestinal tissue obtained from a patient with Crohn's disease, a chronic inflammatory bowel disorder associated with overexpression of pS2, SP and ITF . It would be interesting to investigate the ability of these heterodimers to induce cellular invasion, and to investigate their downstream signaling pathways.
Similarly, the pathways for TFFs and EGFRvIIImediated activation of cellular invasion involve COX-2 and TXA2-R signaling (Rodrigues et al., 2001) , while the invasive activity promoted by the EGFR agonist TGFa was COX-2 and TXA2-R independent. Functional differences between EGFRvIII and normal EGFR have also been characterized. Although the naturally occurring EGFRvIII mutant failed to bind EGF, the receptors can dimerize, and the tyrosine kinase is constitutively activated (Moscatello et al., 1996) , so that the receptor undergoes autophosphorylation as well as phosphorylating substrates such as Shc (Moscatello et al., 1996; Prigent et al., 1996) . Most interestingly, PI3 0 -K is constitutively activated and associated with the EGFRvIII in a molecular complex comprising Gab1 (Moscatello et al., 1998) . However, no increase in GTPbound Ras levels and very low levels of MAPK activity are associated with EGFRvIII expression, consistent with decreased levels of Shc and Grb2 (Montgomery et al., 1995; Moscatello et al., 1996) . Since EGFRvIII is constitutively activated by deletion of its extracellular domain, our data suggest that the crosstalk between pS2/ SP and EGFR would be mediated through agonistindependent transactivation of EGFR. Therefore, pS2-mediated activation of EGFR signaling might occur indirectly through trans-phosphorylation or recruitment of EGFR-associated adaptor molecules. Further inves- Figure 8 Schematic illustration of the pS2 and SP proinvasive pathways connected with cyclooxygenase COX-2 and the EGFR through indirect activation of G-protein-coupled receptors for TXA2 (TXA2-R) or prostaglandins (PG-R). Direct/indirect transactivation of the EGFR by an alternative pathway (?), using the putative pS2/SP recognition sites may also take place. Activated EGFR in turn are connected with src and PI3 0 -kinase activation, leading to transcriptional activation of the immediate response gene COX-2 and creation of a self-activation loop in the signaling system. ROK, Rho-GTPase-associated coil-forming serine/threonine protein kinase Rho kinase; MLC, myosin light chain; proHB-EGF, membrane-anchored heparin-binding EGF tigations should specify the molecular elements directly implicated in the crosstalk between pS2, SP and EGFR in order to provide more information on the TFFs proinvasive signaling pathways.
In conclusion, it is clear that the EGFR contribute to the transforming functions of TFFs as proinvasive factors in the present study and proangiogenic agents in vitro and in vivo (Rodrigues et al., 2001) . Since the proinvasive functions controlled by the src oncogene and the tumor-promoters bile acids are also abolished by disruption of the EGFR signaling pathways, it is therefore conceivable that pharmacological agents and silencer siRNA strategies targeting TFF and EGFR signaling elements may prove to be beneficial for the therapeutic control of cancer progression.
Materials and methods
Cell lines and culture conditions
Madin-Darby canine kidney epithelial cells MDCKts.src transformed by a temperature-sensitive mutant of v-src were cultured in Dubecco's modified Eagle's medium (Gibco BRL, Invitrogen Corporation, Cergy Pontoise, France) supplemented with 10% fetal calf serum (BioWest, Nuaille, France) plus l-glutamine, sodium pyruvate and antibiotics (Gibco BRL, Cergy Pontoise, France), as previously described (Behrens et al., 1993) . MDCKts.src cells display an invasive phenotype at the permissive temperature of 351C for src activation and are not invasive at the restrictive temperature of 401C. The human colorectal cell lines PC/AA/C1 and PCmsrc were grown routinely in 60-mm diameter Petri dishes as described by Empereur et al. (1997) . After transfer of the activated c-src oncogene into the premalignant PC/AA/C1 cell line, PCmsrc cells became tumorigenic in athymic nude mice and invasive upon addition of HGF, leptin or TFFs (Empereur et al., 1997; Attoub et al., 2000; Emami et al., 2001) .
DNA constructs and stable transfections
The expression vectors encoding the dominant-negative (HER-CD533) and constitutively activated forms (EGFRvIII) of the EGFR were from Dr Prenzel and Dr Moscatello, respectively (Redemann et al., 1992; Moscatello et al., 1996) . HER-CD533 encodes an EGFR variant lacking most of the intracellular domain. It has been demonstrated that HER-CD533 efficiently inhibits EGFR-mediated transformation and acts as a dominant-negative variant (Redemann et al., 1992) . EGFRvIII is a deleted form of EGFR lacking an amino-terminal segment of the extracytoplasmic domain containing a cysteine-rich region. This mutation corresponds to a deletion encompassing exons 2-7 and is the most common alteration described in human solid tumors (Yamazaki et al., 1988; Wong et al., 1992) . EGFRvIII is constitutively activated through a ligandindependent dimerization. MDCKts.src and HCT8/S11 cells were stably transfected with plasmids vectors encoding the HER-CD533 or EGFRvIII cDNAs, using the lipofectAMINE plus reagent (Gibco BRL). Control transfections were performed using the corresponding empty vector. After 48 h, cultures were selected for 2 weeks in 0.4 mg/ml G418 (Gibco BRL); resistant colonies were then ring-cloned as individual clones or pooled for analysis of the ectopic expression of HER-CD533 and EGFRvIII by immunoblot analysis.
Western blot analysis
For immunoblotting, cultured cells were homogenized at 41C in lysis buffer containing 0.1 mg/ml phenylmethylsulfonyl fluoride (PMSF), dithiothreitol (DTT), aprotinin, pepstatin A and leupeptin as protease inhibitors. Insoluble material was removed by centrifugation at 41C and 12 000 g. Proteins were resolved in Laemmli buffer, denaturated for 10 min at 1001C, then separated in 8% SDS-PAGE gels and transferred to PVDF membranes (Amersham Pharmacia Biotech, Orsay, France). Membranes were blocked overnight at 41C in phosphate-buffered saline (PBS) containing 5% dried skimmed milk and 0.1% Tween 20. The blots were then probed for 1 h at room temperature with primary monoclonal antibodies (mAbs) directed against the EGFR N-terminal domain (LA22, 1 : 1000, Upstate Biotechnologies, Lake Placid, NY, USA), the Flag epitope of HER-CD533 (Anti-Flag M2, 1 : 3000; Sigma-Aldrich, Saint-Quentin Fallavier, France), and the EGFRvIII C-terminal region (sc-03, 1 : 750, Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Membranes were washed in PBS containing 0.1% Tween 20 (PBS-T) and probed for 1 h with secondary antibody consisting of peroxidaselinked goat anti-mouse lgGs (1 : 2000, Santa Cruz Biotechnologies), then revealed by enhanced chemiluminescence Western detection (ECL, Amersham) according to the manufacturer's instructions.
Collagen invasion assay
For collagen gel invasion by kidney and colonic epithelial cells, Petri dishes were filled with 1.35 ml of neutralized type I collagen and incubated overnight at 371C to allow gelling. Cells were harvested and isolated using Moscona buffer and trypsin/EDTA, then seeded on top of the collagen gels at the density of 0.3 Â 10 6 cells per dish. Dispersed cells were cultured for 24 h at the indicated temperature in the presence or absence of the effectors alone or combined with the appropriate inhibitors of signal transduction pathways. TFFs pS2, SP and ITF were tested at 100 nm concentration representing the maximal response to these proinvasive agents, as previously described . Invasive and superficial cells were counted in 12 fields of 0.157 mm 2 . The invasion index is the percentage of cells invading the gel over the total number of cells (Vleminckx et al., 1991) .
Peptides and reagents
Human ITF and SP were produced in yeast and purified as described . Recombinant hpS2 was produced in Escherichia coli and purified by affinity chromatography (Chadwick et al., 1997) . The nondimerizing Ser 58 pS2 monomer and the Cys 58 pS2 homodimer produced the same extent of stimulation on cellular invasion in HCT8/S11 cells (8.8 to 10%), and their combinations with either SP or ITF do not produce additive or antagonistic responses. Thus, TFFs were used as monomers. Collagen type I was from Upstate Biotechnology (Lake Placid, NY, USA). The EGFR ligands, namely EGF, TGFa, and amphiregulin were from R&D Systems Europe Ltd. (Oxon, UK). The EGFR tyrosine kinase inhibitor ZD1839 (Iressa) was from AstraZeneca (Macclesfield, UK). The prostaglandin H2/thromboxane A2 receptor (TXA2-R) agonist U-46619 and the TXA2-R antagonist SQ29,548 (respectively, designated as U466 and SQ295 in the present study) were from Cayman Chemicals (Ann Arbor, MI, USA). Pertussis toxin and bile acids were from Sigma (Saint Quentin Fallavier, France). The PI3 0 -kinase inhibitor wortmannin (WORT), and the COX-2 inhibitor NS-398 were from Calbiochem (Meudon, France). Clostridium botulinum exoenzyme C3 transferase (abbreviated here as C3 T), which ADP-ribosylates and inactivates the small GTPases RhoA, B, and C but not the Ras, Cdc42, or Rac GTPase (Wilde et al., 2000) , was a generous gift from Dr Flatau (Inserm U452 Nice, France). The toxin was purified according to a modified version of the method published by Saito and Narumiya (Saito and Narumiya, 1997) . The ROCK inhibitor Y27632 was kindly provided by Yoshitomi Pharmaceutical Industries Ltd. (Osaka, Japan).
